ANTIBODY AND ITS APPLICATION

Claims

1. An antibody or antigen-binding fragment thereof that specifically binds to CDCP1, where the antibody or antigen-binding fragment thereof comprises the following heavy chain variable region (VH) and light chain variable region (VL), where the CDRs are defined in accordance with the IMGT numbering system: (1) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence shown as SEQ ID NO: 11, CDR-H2 comprising the sequence shown as SEQ ID NO: 48, and CDR-H3 comprising the sequence shown as SEQ ID NO: 90; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 136, CDR-L2 comprising the sequence presented under SEQ ID NO: 171, and CDR-L3 comprising the sequence presented under SEQ ID NO: 207; or (2) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 2, CDR-H2 comprising the sequence presented under SEQ ID NO: 39, and CDR-H3 comprising the sequence presented under SEQ ID NO: 81; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 125, CDR-L2 comprising the sequence presented under SEQ ID NO: 166, and CDR-L3 comprising the sequence presented under SEQ ID NO: 199; or (3) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence shown as SEQ ID NO: 14, CDR-H2 comprising the sequence shown as SEQ ID NO: 52, and CDR-H3 comprising the sequence shown as SEQ ID NO: 95; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 140, CDR-L2 comprising the sequence presented under SEQ ID NO: 175, and CDR-L3 comprising the sequence presented under SEQ ID NO: 211; or (4) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 1, CDR-H2 comprising the sequence presented under SEQ ID NO: 38, and CDR-H3 comprising the sequence presented under SEQ ID NO: 80; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 124, CDR-L2 comprising the sequence presented under SEQ ID NO: 164, and CDR-L3 comprising the sequence presented under SEQ ID NO: 197; or (5) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 1, CDR-H2 comprising the sequence presented under SEQ ID NO: 38, and CDR-H3 comprising the sequence presented under SEQ ID NO: 80; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 125, CDR-L2 comprising the sequence presented under SEQ ID NO: 165, and CDR-L3 comprising the sequence presented under SEQ ID NO: 198; or (6) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 3, CDR-H2 comprising the sequence presented under SEQ ID NO: 39, and CDR-H3 comprising the sequence presented under SEQ ID NO: 81; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 126, CDR-L2 comprising the sequence presented under SEQ ID NO: 167, and CDR-L3 comprising the sequence presented under SEQ ID NO: 200; or (7) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 4, CDR-H2 comprising the sequence presented under SEQ ID NO: 40, and CDR-H3 comprising the sequence presented under SEQ ID NO: 82; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 127, CDR-L2 comprising the sequence presented under SEQ ID NO: 168, and CDR-L3 comprising the sequence presented under SEQ ID NO: 201; or (8) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 5, CDR-H2 comprising the sequence presented under SEQ ID NO: 41, and CDR-H3 comprising the sequence presented under SEQ ID NO: 83; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 128, CDR-L2 comprising the sequence presented under SEQ ID NO: 169, and CDR-L3 comprising the sequence presented under SEQ ID NO: 202; or (9) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 6, CDR-H2 comprising the sequence presented under SEQ ID NO: 42, and CDR-H3 comprising the sequence presented under SEQ ID NO: 84; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 129, CDR-L2 comprising the sequence presented under SEQ ID NO: 170, and CDR-L3 comprising the sequence presented under SEQ ID NO: 203; or (10) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 6, CDR-H2 comprising the sequence presented under SEQ ID NO: 43, and CDR-H3 comprising the sequence presented under SEQ ID NO: 85; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 130, CDR-L2 comprising the sequence presented under SEQ ID NO: 170, and CDR-L3 comprising the sequence presented under SEQ ID NO: 203; or (11) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 7, CDR-H2 comprising the sequence presented under SEQ ID NO: 44, and CDR-H3 comprising the sequence presented under SEQ ID NO: 86; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 131, CDR-L2 comprising the sequence presented under SEQ ID NO: 171, and CDR-L3 comprising the sequence presented under SEQ ID NO: 204; or (12) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 7, CDR-H2 comprising the sequence presented under SEQ ID NO: 44, and CDR-H3 comprising the sequence presented under SEQ ID NO: 86; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 132, CDR-L2 comprising the sequence presented under SEQ ID NO: 171, and CDR-L3 comprising the sequence presented under SEQ ID NO: 204; or (13) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 7, CDR-H2 comprising the sequence presented under SEQ ID NO: 44, and CDR-H3 comprising the sequence presented under SEQ ID NO: 86; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 130, CDR-L2 comprising the sequence presented under SEQ ID NO: 170, and CDR-L3 comprising the sequence presented under SEQ ID NO: 203; or (14) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 8, CDR-H2 comprising the sequence presented under SEQ ID NO: 45, and CDR-H3 comprising the sequence presented under SEQ ID NO: 87; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 133, CDR-L2 comprising the sequence presented under SEQ ID NO: 170, and CDR-L3 comprising the sequence presented under SEQ ID NO: 203; or (15) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 9, CDR-H2 comprising the sequence presented under SEQ ID NO: 46, and CDR-H3 comprising the sequence presented under SEQ ID NO: 88; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 134, CDR-L2 comprising the sequence presented under SEQ ID NO: 164, and CDR-L3 comprising the sequence presented under SEQ ID NO: 205; or (16) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 10, CDR-H2 comprising the sequence presented under SEQ ID NO: 47, and CDR-H3 comprising the sequence presented under SEQ ID NO: 89; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 135, CDR-L2 comprising the sequence presented under SEQ ID NO: 172, and CDR-L3 comprising the sequence presented under SEQ ID NO: 206; or (17) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 12, CDR-H2 comprising the sequence presented under SEQ ID NO: 48, and CDR-H3 comprising the sequence presented under SEQ ID NO: 91; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 136, CDR-L2 comprising the sequence presented under SEQ ID NO: 171, and CDR-L3 comprising the sequence presented under SEQ ID NO: 207; or (18) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 11, CDR-H2 comprising the sequence presented under SEQ ID NO: 48, and CDR-H3 comprising the sequence presented under SEQ ID NO: 90; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 136, CDR-L2 comprising the sequence presented under SEQ ID NO: 171, and CDR-L3 comprising the sequence presented under SEQ ID NO: 207; or (19) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 13, CDR-H2 comprising the sequence presented under SEQ ID NO: 49, and CDR-H3 comprising the sequence presented under SEQ ID NO: 92; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 137, CDR-L2 comprising the sequence presented under SEQ ID NO: 173, and CDR-L3 comprising the sequence presented under SEQ ID NO: 208; or (20) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 13, CDR-H2 comprising the sequence presented under SEQ ID NO: 50, and CDR-H3 comprising the sequence presented under SEQ ID NO: 93; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 138, CDR-L2 comprising the sequence presented under SEQ ID NO: 170, and CDR-L3 comprising the sequence presented under SEQ ID NO: 209; or (21) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 13, CDR-H2 comprising the sequence presented under SEQ ID NO: 51, and CDR-H3 comprising the sequence presented under SEQ ID NO: 94; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 139, CDR-L2 comprising the sequence presented under SEQ ID NO: 170, and CDR-L3 comprising the sequence presented under SEQ ID NO: 210; or (22) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 15, CDR-H2 comprising the sequence presented under SEQ ID NO: 53, and CDR-H3 comprising the sequence presented under SEQ ID NO: 96; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 124, CDR-L2 comprising the sequence presented under SEQ ID NO: 164, and CDR-L3 comprising the sequence presented under SEQ ID NO: 212; or (23) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 16, CDR-H2 comprising the sequence presented under SEQ ID NO: 54, and CDR-H3 comprising the sequence presented under SEQ ID NO: 97; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 141, CDR-L2 comprising the sequence presented under SEQ ID NO: 172, and CDR-L3 comprising the sequence presented under SEQ ID NO: 213; or (24) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 17, CDR-H2 comprising the sequence presented under SEQ ID NO: 55, and CDR-H3 comprising the sequence presented under SEQ ID NO: 98; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 126, CDR-L2 comprising the sequence presented under SEQ ID NO: 174, and CDR-L3 comprising the sequence presented under SEQ ID NO: 214; or (25) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 18, CDR-H2 comprising the sequence presented under SEQ ID NO: 56, and CDR-H3 comprising the sequence presented under SEQ ID NO: 99; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 142, CDR-L2 comprising the sequence presented under SEQ ID NO: 176, and CDR-L3 comprising the sequence presented under SEQ ID NO: 215; or (26) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 19, CDR-H2 comprising the sequence presented under SEQ ID NO: 57, and CDR-H3 comprising the sequence presented under SEQ ID NO: 100; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 143, CDR-L2 comprising the sequence presented under SEQ ID NO: 177, and CDR-L3 comprising the sequence presented under SEQ ID NO: 216; or (27) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 20, CDR-H2 comprising the sequence presented under SEQ ID NO: 58, and CDR-H3 comprising the sequence presented under SEQ ID NO: 101; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 144, CDR-L2 comprising the sequence presented under SEQ ID NO: 176, and CDR-L3 comprising the sequence presented under SEQ ID NO: 215; or (28) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 21, CDR-H2 comprising the sequence presented under SEQ ID NO: 59, and CDR-H3 comprising the sequence presented under SEQ ID NO: 102; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 127, CDR-L2 comprising the sequence presented under SEQ ID NO: 168, and CDR-L3 comprising the sequence presented under SEQ ID NO: 217; or (29) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 21, CDR-H2 comprising the sequence presented under SEQ ID NO: 60, and CDR-H3 comprising the sequence presented under SEQ ID NO: 102; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 127, CDR-L2 comprising the sequence presented under SEQ ID NO: 168, and CDR-L3 comprising the sequence presented under SEQ ID NO: 217; or (30) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 13, CDR-H2 comprising the sequence presented under SEQ ID NO: 49, and CDR-H3 comprising the sequence presented under SEQ ID NO: 103; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 144, CDR-L2 comprising the sequence presented under SEQ ID NO: 169, and CDR-L3 comprising the sequence presented under SEQ ID NO: 218; or (31) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 22, CDR-H2 comprising the sequence presented under SEQ ID NO: 61, and CDR-H3 comprising the sequence presented under SEQ ID NO: 104; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 145, CDR-L2 comprising the sequence presented under SEQ ID NO: 178, and CDR-L3 comprising the sequence presented under SEQ ID NO: 219; or (32) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 17, CDR-H2 comprising the sequence presented under SEQ ID NO: 62, and CDR-H3 comprising the sequence presented under SEQ ID NO: 105; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 141, CDR-L2 comprising the sequence presented under SEQ ID NO: 172, and CDR-L3 comprising the sequence presented under SEQ ID NO: 220; or (33) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 17, CDR-H2 comprising the sequence presented under SEQ ID NO: 63, and CDR-H3 comprising the sequence presented under SEQ ID NO: 106; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 126, CDR-L2 comprising the sequence presented under SEQ ID NO: 179, and CDR-L3 comprising the sequence presented under SEQ ID NO: 221; or (34) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 23, CDR-H2 comprising the sequence presented under SEQ ID NO: 64, and CDR-H3 comprising the sequence presented under SEQ ID NO: 107; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 146, CDR-L2 comprising the sequence presented under SEQ ID NO: 180, and CDR-L3 comprising the sequence presented under SEQ ID NO: 222; or (35) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 24, CDR-H2 comprising the sequence presented under SEQ ID NO: 65, and CDR-H3 comprising the sequence presented under SEQ ID NO: 108; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 147, CDR-L2 comprising the sequence presented under SEQ ID NO: 181, and CDR-L3 comprising the sequence presented under SEQ ID NO: 223; or (36) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 25, CDR-H2 comprising the sequence presented under SEQ ID NO: 65, and CDR-H3 comprising the sequence presented under SEQ ID NO: 108; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 148, CDR-L2 comprising the sequence presented under SEQ ID NO: 181, and CDR-L3 comprising the sequence presented under SEQ ID NO: 224; or (37) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 26, CDR-H2 comprising the sequence presented under SEQ ID NO: 66, and CDR-H3 comprising the sequence presented under SEQ ID NO: 109; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 149, CDR-L2 comprising the sequence presented under SEQ ID NO: 182, and CDR-L3 comprising the sequence presented under SEQ ID NO: 225; or (38) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 27, CDR-H2 comprising the sequence presented under SEQ ID NO: 67, and CDR-H3 comprising the sequence presented under SEQ ID NO: 110; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 150, CDR-L2 comprising the sequence presented under SEQ ID NO: 183, and CDR-L3 comprising the sequence presented under SEQ ID NO: 226; or (39) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 28, CDR-H2 comprising the sequence presented under SEQ ID NO: 68, and CDR-H3 comprising the sequence presented under SEQ ID NO: 111; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 151, CDR-L2 comprising the sequence presented under SEQ ID NO: 184, and CDR-L3 comprising the sequence presented under SEQ ID NO: 227; or (40) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 29, CDR-H2 comprising the sequence presented under SEQ ID NO: 69, and CDR-H3 comprising the sequence presented under SEQ ID NO: 112; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 152, CDR-L2 comprising the sequence presented under SEQ ID NO: 185, and CDR-L3 comprising the sequence presented under SEQ ID NO: 222; or (41) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 30, CDR-H2 comprising the sequence presented under SEQ ID NO: 70, and CDR-H3 comprising the sequence presented under SEQ ID NO: 113; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 153, CDR-L2 comprising the sequence presented under SEQ ID NO: 186, and CDR-L3 comprising the sequence presented under SEQ ID NO: 228; or (42) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 31, CDR-H2 comprising the sequence presented under SEQ ID NO: 71, and CDR-H3 comprising the sequence presented under SEQ ID NO: 114; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 154, CDR-L2 comprising the sequence presented under SEQ ID NO: 187, and CDR-L3 comprising the sequence presented under SEQ ID NO: 229; or (43) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 32, CDR-H2 comprising the sequence presented under SEQ ID NO: 72, and CDR-H3 comprising the sequence presented under SEQ ID NO: 115; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 155, CDR-L2 comprising the sequence presented under SEQ ID NO: 188, and CDR-L3 comprising the sequence presented under SEQ ID NO: 230; or (44) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 33, CDR-H2 comprising the sequence presented under SEQ ID NO: 73, and CDR-H3 comprising the sequence presented under SEQ ID NO: 116; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 156, CDR-L2 comprising the sequence presented under SEQ ID NO: 189, and CDR-L3 comprising the sequence presented under SEQ ID NO: 231; or (45) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 34, CDR-H2 comprising the sequence presented under SEQ ID NO: 74, and CDR-H3 comprising the sequence presented under SEQ ID NO: 117; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 157, CDR-L2 comprising the sequence presented under SEQ ID NO: 190, and CDR-L3 comprising the sequence presented under SEQ ID NO: 232; or (46) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 35, CDR-H2 comprising the sequence presented under SEQ ID NO: 75, and CDR-H3 comprising the sequence presented under SEQ ID NO: 118; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 158, CDR-L2 comprising the sequence presented under SEQ ID NO: 191, and CDR-L3 comprising the sequence presented under SEQ ID NO: 233; or (47) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 26, CDR-H2 comprising the sequence presented under SEQ ID NO: 76, and CDR-H3 comprising the sequence presented under SEQ ID NO: 119; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 159, CDR-L2 comprising the sequence presented under SEQ ID NO: 192, and CDR-L3 comprising the sequence presented under SEQ ID NO: 234; or (48) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 24, CDR-H2 comprising the sequence presented under SEQ ID NO: 77, and CDR-H3 comprising the sequence presented under SEQ ID NO: 120; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 160, CDR-L2 comprising the sequence presented under SEQ ID NO: 193, and CDR-L3 comprising the sequence presented under SEQ ID NO: 235; or (49) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 36, CDR-H2 comprising the sequence presented under SEQ ID NO: 78, and CDR-H3 comprising the sequence presented under SEQ ID NO: 121; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 161, CDR-L2 comprising the sequence presented under SEQ ID NO: 194, and CDR-L3 comprising the sequence presented under SEQ ID NO: 236; or (50) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 32, CDR-H2 comprising the sequence presented under SEQ ID NO: 79, and CDR-H3 comprising the sequence presented under SEQ ID NO: 122; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 162, CDR-L2 comprising the sequence presented under SEQ ID NO: 195, and CDR-L3 comprising the sequence presented under SEQ ID NO: 237; or (51) VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 37, CDR-H2 comprising the sequence presented under SEQ ID NO: 79, and CDR-H3 comprising the sequence presented under SEQ ID NO: 123; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 163, CDR-L2 comprising the sequence presented under SEQ ID NO: 196, and CDR-L3 comprising the sequence presented under SEQ ID NO: 238; preferably the antibody or antigen-binding fragment thereof comprises the following heavy chain variable region (VH) and light chain variable region (VL), wherein the CDRs are defined in accordance with the Kabat numbering system: (1) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence shown as SEQ ID NO: 392, CDR-H2 comprising the sequence shown as SEQ ID NO: 393, and CDR-H3 comprising the sequence shown as SEQ ID NO: 394; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 395, CDR-L2 comprising the sequence presented under SEQ ID NO: 396, and CDR-L3 comprising the sequence presented under SEQ ID NO: 207; or (2) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 362, CDR-H2 comprising the sequence presented under SEQ ID NO: 363, and CDR-H3 comprising the sequence presented under SEQ ID NO: 364; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 365, CDR-L2 comprising the sequence presented under SEQ ID NO: 366, and CDR-L3 comprising the sequence presented under SEQ ID NO: 199; or (3) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 377, CDR-H2 comprising the sequence presented under SEQ ID NO: 378, and CDR-H3 comprising the sequence presented under SEQ ID NO: 379; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 380, CDR-L2 comprising the sequence presented under SEQ ID NO: 381, and CDR-L3 comprising the sequence presented under SEQ ID NO: 211; or CDRs are defined according to the AbM numbering system: (1) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence shown as SEQ ID NO: 397, CDR-H2 comprising the sequence shown as SEQ ID NO: 398, and CDR-H3 comprising the sequence shown as SEQ ID NO: 394; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 395, CDR-L2 comprising the sequence presented under SEQ ID NO: 396, and CDR-L3 comprising the sequence presented under SEQ ID NO: 207; or (2) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 367, CDR-H2 comprising the sequence presented under SEQ ID NO: 368, and CDR-H3 comprising the sequence presented under SEQ ID NO: 364; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 365, CDR-L2 comprising the sequence presented under SEQ ID NO: 366, and CDR-L3 comprising the sequence presented under SEQ ID NO: 199; or (3) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 382, CDR-H2 comprising the sequence presented under SEQ ID NO: 383, and CDR-H3 comprising the sequence presented under SEQ ID NO: 379; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 380, CDR-L2 comprising the sequence presented under SEQ ID NO: 381, and CDR-L3 comprising the sequence presented under SEQ ID NO: 211; or CDRs are defined according to the numbering system according to Chothia: (1) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence shown as SEQ ID NO: 399, CDR-H2 comprising the sequence shown as SEQ ID NO: 400, and CDR-H3 comprising the sequence shown as SEQ ID NO: 394; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 395, CDR-L2 comprising the sequence presented under SEQ ID NO: 396, and CDR-L3 comprising the sequence presented under SEQ ID NO: 207; or (2) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 369, CDR-H2 comprising the sequence presented under SEQ ID NO: 370, and CDR-H3 comprising the sequence presented under SEQ ID NO: 364; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 365, CDR-L2 comprising the sequence presented under SEQ ID NO: 366, and CDR-L3 comprising the sequence presented under SEQ ID NO: 199; or (3) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 384, CDR-H2 comprising the sequence presented under SEQ ID NO: 385, and CDR-H3 comprising the sequence presented under SEQ ID NO: 379; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 380, CDR-L2 comprising the sequence presented under SEQ ID NO: 381, and CDR-L3 comprising the sequence presented under SEQ ID NO: 211; or CDRs are defined in accordance with the contact residue numbering system: (1) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 401, CDR-H2 comprising the sequence presented under SEQ ID NO: 402, and CDR-H3 comprising the sequence presented under SEQ ID NO: 403; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 404, CDR-L2 comprising the sequence presented under SEQ ID NO: 405, and CDR-L3 comprising the sequence presented under SEQ ID NO: 406; or (2) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence shown as SEQ ID NO: 371, CDR-H2 comprising the sequence shown as SEQ ID NO: 372, and CDR-H3 comprising the sequence shown as SEQ ID NO: 373; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 374, CDR-L2 comprising the sequence presented under SEQ ID NO: 375, and CDR-L3 comprising the sequence presented under SEQ ID NO: 376; or (3) a VH comprising the following 3 CDRs: CDR-H1 comprising the sequence presented under SEQ ID NO: 386, CDR-H2 comprising the sequence presented under SEQ ID NO: 387, and CDR-H3 comprising the sequence presented under SEQ ID NO: 388; and VL comprising the following 3 CDRs: CDR-L1 comprising the sequence presented under SEQ ID NO: 389, CDR-L2 comprising the sequence presented under SEQ ID NO: 390, and CDR-L3 comprising the sequence presented under SEQ ID NO:

391.

2. An antibody or antigen-binding fragment thereof that specifically binds to CDCP1, according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL) selected from any of the following groups: (1) VH from the sequence presented under SEQ ID NO: 254 and VL from the sequence presented under SEQ ID NO: 304; (2) VH from the sequence presented under SEQ ID NO: 343 and VL from the sequence presented under SEQ ID NO: 354; (3) VH from the sequence presented under SEQ ID NO: 343 and VL from the sequence presented under SEQ ID NO: 355; (4) VH from the sequence presented under SEQ ID NO: 343 and VL from the sequence presented under SEQ ID NO: 356; (5) VH from the sequence presented under SEQ ID NO: 344 and VL from the sequence presented under SEQ ID NO: 354; (6) VH from the sequence presented under SEQ ID NO: 344 and VL from the sequence presented under SEQ ID NO: 355; (7) VH from the sequence presented under SEQ ID NO: 344 and VL from the sequence presented under SEQ ID NO: 356; (8) VH from the sequence presented under SEQ ID NO: 345 and VL from the sequence presented under SEQ ID NO: 354; (9) VH from the sequence presented under SEQ ID NO: 345 and VL from the sequence presented under SEQ ID NO: 355; (10) VH from the sequence presented under SEQ ID NO: 345 and VL from the sequence presented under SEQ ID NO: 356; (11) VH from the sequence presented under SEQ ID NO: 346 and VL from the sequence presented under SEQ ID NO: 354; (12) VH from the sequence presented under SEQ ID NO: 346 and VL from the sequence presented under SEQ ID NO: 355; (13) VH from the sequence presented under SEQ ID NO: 346 and VL from the sequence presented under SEQ ID NO: 356; (14) VH from the sequence presented under SEQ ID NO: 240 and VL from the sequence presented under SEQ ID NO: 291; (15) VH from the sequence presented under SEQ ID NO: 339 and VL from the sequence presented under SEQ ID NO: 351; (16) VH from the sequence presented under SEQ ID NO: 339 and VL from the sequence presented under SEQ ID NO: 352; (17) VH from the sequence presented under SEQ ID NO: 339 and VL from the sequence presented under SEQ ID NO: 353; (18) VH from the sequence presented under SEQ ID NO: 340 and VL from the sequence presented under SEQ ID NO: 351; (19) VH from the sequence presented under SEQ ID NO: 340 and VL from the sequence presented under SEQ ID NO: 352; (20) VH from the sequence presented under SEQ ID NO: 340 and VL from the sequence presented under SEQ ID NO: 353; (21) VH from the sequence presented under SEQ ID NO: 341 and VL from the sequence presented under SEQ ID NO: 351; (22) VH from the sequence presented under SEQ ID NO: 341 and VL from the sequence presented under SEQ ID NO: 352; (23) VH from the sequence presented under SEQ ID NO: 341 and VL from the sequence presented under SEQ ID NO: 353; (24) VH from the sequence presented under SEQ ID NO: 342 and VL from the sequence presented under SEQ ID NO: 351; (25) VH from the sequence presented under SEQ ID NO: 342 and VL from the sequence presented under SEQ ID NO: 352; (26) VH from the sequence presented under SEQ ID NO: 342 and VL from the sequence presented under SEQ ID NO: 353; (27) VH from the sequence presented under SEQ ID NO: 258 and VL from the sequence presented under SEQ ID NO: 308; (28) VH from the sequence presented under SEQ ID NO: 347 and VL from the sequence presented under SEQ ID NO: 357; (29) VH from the sequence presented under SEQ ID NO: 347 and VL from the sequence presented under SEQ ID NO: 358; (30) VH from the sequence presented under SEQ ID NO: 347 and VL from the sequence presented under SEQ ID NO: 359; (31) VH from the sequence presented under SEQ ID NO: 348 and VL from the sequence presented under SEQ ID NO: 357; (32) VH from the sequence presented under SEQ ID NO: 348 and VL from the sequence presented under SEQ ID NO: 358; (33) VH from the sequence presented under SEQ ID NO: 348 and VL from the sequence presented under SEQ ID NO: 359; (34) VH from the sequence presented under SEQ ID NO: 349 and VL from the sequence presented under SEQ ID NO: 357; (35) VH from the sequence presented under SEQ ID NO: 349 and VL from the sequence presented under SEQ ID NO: 358; (36) VH from the sequence presented under SEQ ID NO: 349 and VL from the sequence presented under SEQ ID NO: 359; (37) VH from the sequence presented under SEQ ID NO: 350 and VL from the sequence presented under SEQ ID NO: 357; (38) VH from the sequence presented under SEQ ID NO: 350 and VL from the sequence presented under SEQ ID NO: 358; (39) VH from the sequence presented under SEQ ID NO: 350 and VL from the sequence presented under SEQ ID NO: 359; (40) VH from the sequence presented under SEQ ID NO: 239 and VL from the sequence presented under SEQ ID NO: 289; (41) VH from the sequence presented under SEQ ID NO: 239 and VL from the sequence presented under SEQ ID NO: 290; (42) VH from the sequence presented under SEQ ID NO: 241 and VL from the sequence presented under SEQ ID NO: 292; (43) VH from the sequence presented under SEQ ID NO: 242 and VL from the sequence presented under SEQ ID NO: 293; (44) VH from the sequence presented under SEQ ID NO: 243 and VL from the sequence presented under SEQ ID NO: 294; (45) VH from the sequence presented under SEQ ID NO: 244 and VL from the sequence presented under SEQ ID NO: 295; (46) VH from the sequence presented under SEQ ID NO: 245 and VL from the sequence presented under SEQ ID NO: 296; (47) VH from the sequence presented under SEQ ID NO: 246 and VL from the sequence presented under SEQ ID NO: 297; (48) VH from the sequence presented under SEQ ID NO: 247 and VL from the sequence presented under SEQ ID NO: 298; (49) VH from the sequence presented under SEQ ID NO: 248 and VL from the sequence presented under SEQ ID NO: 296; (50) VH from the sequence presented under SEQ ID NO: 249 and VL from the sequence presented under SEQ ID NO: 299; (51) VH from the sequence presented under SEQ ID NO: 250 and VL from the sequence presented under SEQ ID NO: 300; (52) VH from the sequence presented under SEQ ID NO: 251 and VL from the sequence presented under SEQ ID NO: 301; (53) VH from the sequence presented under SEQ ID NO: 252 and VL from the sequence presented under SEQ ID NO: 302; (54) VH from the sequence presented under SEQ ID NO: 253 and VL from the sequence presented under SEQ ID NO: 303; (55) VH from the sequence presented under SEQ ID NO: 255 and VL from the sequence presented under SEQ ID NO: 305; (56) VH from the sequence presented under SEQ ID NO: 256 and VL from the sequence presented under SEQ ID NO: 306; (57) VH from the sequence presented under SEQ ID NO: 257 and VL from the sequence presented under SEQ ID NO: 307; (58) VH from the sequence presented under SEQ ID NO: 259 and VL from the sequence presented under SEQ ID NO: 309; (59) VH from the sequence presented under SEQ ID NO: 260 and VL from the sequence presented under SEQ ID NO: 310; (60) VH from the sequence presented under SEQ ID NO: 261 and VL from the sequence presented under SEQ ID NO: 311; (61) VH from the sequence presented under SEQ ID NO: 262 and VL from the sequence presented under SEQ ID NO: 312; (62) VH from the sequence presented under SEQ ID NO: 263 and VL from the sequence presented under SEQ ID NO: 313; (63) VH from the sequence presented under SEQ ID NO: 264 and VL from the sequence presented under SEQ ID NO: 314; (64) VH from the sequence presented under SEQ ID NO: 265 and VL from the sequence presented under SEQ ID NO: 315; (65) VH from the sequence presented under SEQ ID NO: 266 and VL from the sequence presented under SEQ ID NO: 316; (66) VH from the sequence presented under SEQ ID NO: 267 and VL from the sequence presented under SEQ ID NO: 317; (67) VH from the sequence presented under SEQ ID NO: 268 and VL from the sequence presented under SEQ ID NO: 318; (68) VH from the sequence presented under SEQ ID NO: 269 and VL from the sequence presented under SEQ ID NO: 319; (69) VH from the sequence presented under SEQ ID NO: 270 and VL from the sequence presented under SEQ ID NO: 320; (70) VH from the sequence presented under SEQ ID NO: 271 and VL from the sequence presented under SEQ ID NO: 321; (71) VH from the sequence presented under SEQ ID NO: 272 and VL from the sequence presented under SEQ ID NO: 322; (72) VH from the sequence presented under SEQ ID NO: 273 and VL from the sequence presented under SEQ ID NO: 323; (73) VH from the sequence presented under SEQ ID NO: 274 and VL from the sequence presented under SEQ ID NO: 324; (74) VH from the sequence presented under SEQ ID NO: 275 and VL from the sequence presented under SEQ ID NO: 325; (75) VH from the sequence presented under SEQ ID NO: 276 and VL from the sequence presented under SEQ ID NO: 326; (76) VH from the sequence presented under SEQ ID NO: 277 and VL from the sequence presented under SEQ ID NO: 327; (77) VH from the sequence presented under SEQ ID NO: 278 and VL from the sequence presented under SEQ ID NO: 328; (78) VH from the sequence presented under SEQ ID NO: 279 and VL from the sequence presented under SEQ ID NO: 329; (79) VH from the sequence presented under SEQ ID NO: 280 and VL from the sequence presented under SEQ ID NO: 330; (80) VH from the sequence presented under SEQ ID NO: 281 and VL from the sequence presented under SEQ ID NO: 331; (81) VH from the sequence presented under SEQ ID NO: 282 and VL from the sequence presented under SEQ ID NO: 332; (82) VH from the sequence presented under SEQ ID NO: 283 and VL from the sequence presented under SEQ ID NO: 333; (83) VH from the sequence presented under SEQ ID NO: 284 and VL from the sequence presented under SEQ ID NO: 334; (84) VH from the sequence presented under SEQ ID NO: 285 and VL from the sequence presented under SEQ ID NO: 335; (85) VH from the sequence presented under SEQ ID NO: 286 and VL from the sequence presented under SEQ ID NO: 336; (86) VH from the sequence presented under SEQ ID NO: 287 and VL from the sequence presented under SEQ ID NO: 337; (87) VH from the sequence presented under SEQ ID NO: 288 and VL from the sequence presented under SEQ ID NO: 338; optionally, in the case of VH and VL, when compared to any of groups (1) to (87), VH has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity with VH in any of groups (1) to (87); and the VL has at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to a VL in any of groups (1) to (87).

3. An antibody or antigen-binding fragment thereof that specifically binds to CDCP1 according to claim 1 or 2, wherein the antibody or antigen-binding fragment thereof is selected from a Fab fragment, a Fab' fragment, a F(ab)'2 fragment, a single-chain antibody, a disulfide-stabilized Fv protein (dsFv); preferably the single chain antibody is selected from scFv or (scFv)2; and / or the antibody or antigen-binding fragment thereof is a murine antibody, a chimeric antibody, a humanized antibody, or an antibody obtained from another species (e.g., rabbits, camels, or sharks); and / or the antibody or antigen-binding fragment thereof additionally comprises a heavy chain constant region (CH) and a light chain constant region (CL); preferably the heavy chain constant region is selected from a heavy chain constant region or a variant thereof from IgG, IgM, IgE, IgD or IgA; and / or the light chain constant region is selected from a light chain constant region or a variant thereof from kappa or lambda; the variant is characterized by a substitution, deletion, or addition of one or more amino acids (e.g. a substitution, deletion, or addition of no more than 20, no more than 15, no more than 10, or no more than 5 amino acids; e.g. a substitution, deletion, or addition of 1, 2, 3, 4, or 5 amino acids) compared to the wild-type sequence from which it is derived; more preferably, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region and a light chain constant region selected from the following: (1) the constant region of the human IgG1 heavy chain; (2) the constant region of the human IgG1 light chain; even more preferably, the heavy chain constant region (CH) of the antibody or antigen-binding fragment thereof comprises the amino acid sequence set forth under SEQ ID NO: 360; and / or the light chain constant region is a human IgG1 kappa light chain constant region; the light chain constant region (CL) comprises the amino acid sequence set forth in SEQ ID NO:

361.

4. An antibody or antigen-binding fragment thereof that specifically binds to CDCP1, according to any one of claims 1-3, wherein antibody or its antigen-binding fragment bind to CDCP1 (e.g., human CDCP1) with a KD of less than about 500 nM, such as less than about 100 nM, 50 nM, 40 nM, 20 nM, 10 nM, 1 nM, 0.1 nM, 0.01 nM, or less; and / or bind to CDCP1-expressing tumor cells with EC 50 less than about 500 nM, such as less than about 100 nM, 10 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, 0.1 nM, 0.01 nM or less; preferably EC 50 measured by flow cytometry or cell-based competitive ELISA; preferably the antibody or antigen-binding fragment thereof is capable or incapable of inducing endocytosis; and / or the antibody or its antigen-binding fragment is not capable of stimulating tumor cell migration; and / or the antibody or its antigen-binding fragment is capable of suppressing tumor metastasis.

5. A multispecific antibody comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, preferably the multispecific antibody is a bispecific antibody, or a trispecific antibody, or a tetraspecific antibody.

6. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment thereof according to any one of claims 1-4 or a multispecific antibody according to claim 5.

7. A vector containing a nucleic acid molecule according to claim 6.

8. A host cell containing a nucleic acid molecule according to claim 6 or a vector according to claim 7.

9. A method for producing an antibody or its antigen-binding fragment or a multispecific antibody that specifically binds to CDCP1, wherein the method comprises culturing the host cell of claim 8 under conditions that provide expression of the antibody or its antigen-binding fragment or multispecific antibody, and recovering the antibody or its antigen-binding fragment or multispecific antibody from the cultured host cell culture.

10. A conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate comprises an antibody or an antigen-binding fragment thereof according to any one of claims 1-4 or a multispecific antibody according to claim 5 and a binding fragment; wherein the antibody or antigen-binding fragment thereof or the multispecific antibody is linked to the binding fragment directly or via a linker; preferably, the binding moiety is selected from a detectable label (e.g., a radioisotope, a fluorescent substance, a luminescent substance, a dye, or an enzyme) or a therapeutic agent (e.g., a nuclide, an immune agonist, an immunosuppressant, a cytokine, a toxin, or other active substance that inhibits tumor cell growth, stimulates apoptosis, or necrosis of tumor cells).

11. A conjugate or a pharmaceutically acceptable salt thereof according to claim 10, wherein the structure of the conjugate is shown in formula (I): A-(LD) p (I), L is present or absent; Where A is an antibody or antigen-binding fragment thereof according to any one of claims 1-4 or a multispecific antibody according to claim 5; L is a linker, preferably the linker is a vc-linker, the structure of which is as follows: ; D is a linking fragment; preferably the binding moiety is an immune activator comprising a TLR, STING, OND, CpG, LPS, SEB, SEA or SEC activator; or the binding moiety is a cytokine that includes IL-6, IL-15, IL-12, IL-1b, or IL-23; or the binding moiety is a toxin that provides a cytotoxic agent; more preferably, the cytotoxic agent is selected from camptothecins (e.g., SN-38), maytansines (e.g., maytansine DM1 / 4), pyrrolobenzodiazepines (PBD), and auristatin (e.g., monomethyl auristatin E / F); p-value is greater than or equal to 0; preferably p-value is 0-8; more preferably, LD is vc-MMAE, characterized by the structure shown below: .

12. A conjugate or a pharmaceutically acceptable salt thereof, wherein the structure of the conjugate is shown in formula (I): A-(LD) p (I); Where A is an antibody that specifically binds to CDCP1, comprising a heavy chain and a light chain; the heavy chain comprises a heavy chain variable region and a heavy chain constant region, the light chain comprises a light chain variable region and a light chain constant region; the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) selected from any of the following groups: (1) VH from the sequence presented under SEQ ID NO: 340 and VL from the sequence presented under SEQ ID NO: 351; (2) VH from the sequence presented under SEQ ID NO: 348 and VL from the sequence presented under SEQ ID NO: 358; and (3) VH from the sequence presented under SEQ ID NO: 344 and VL from the sequence presented under SEQ ID NO: 354; the antibody further comprises a heavy chain constant region from the sequence presented under SEQ ID NO: 360 and a light chain constant region from the sequence presented under SEQ ID NO: 361; The structure of L is shown below: ; D is monomethyl auristatin E; the value of p is greater than or equal to 0; preferably, p is 0-8.

13. A pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof according to any one of claims 1-4, or a multispecific antibody according to claim 5, or a conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 10-12 and a pharmaceutically acceptable carrier and / or excipient; preferably, the pharmaceutical composition additionally contains an additional pharmaceutically active agent; more preferably, the additional pharmaceutically active agent is a drug having antitumor activity, such as a chemotherapeutic drug (e.g., a platinum-based drug), a small molecule inhibitor; and / or the additional pharmaceutically active agent is a drug related to immunotherapy, such as an immune checkpoint inhibitor (e.g., a PD-1, PD-L1, or CTLA-4 inhibitor), an immune enhancing drug (e.g., an interferon, an interleukin), or an immune system activator (e.g., a TLR, OND, CpG, LPS, SEB, SEA, STING, or SEC activator); and / or the additional pharmaceutically active agent is an oncolytic virus, an immune cell or an engineered immune cell and / or the additional pharmaceutically active agent is a radioactive substance or a chromogenic agent.

14. A kit containing an antibody or an antigen-binding fragment thereof according to any one of claims 1-4, or a multispecific antibody according to claim 5, or a conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 10-12, or a pharmaceutical composition according to claim 13.

15. A method for detecting the presence or level of CDCP1 in a sample, wherein the method comprises contacting the sample with an antibody or antigen-binding fragment thereof according to any one of claims 1-4, or a multispecific antibody according to claim 5, or a conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 10-12, or a pharmaceutical composition according to claim 13 under conditions that ensure the formation of a complex between the antibody or antigen-binding fragment thereof, the multispecific antibody, the conjugate or the pharmaceutical composition and CDCP1, and detecting the formation of the complex.

16. An antibody or antigen-binding fragment thereof according to any one of claims 1-4, or a multispecific antibody according to claim 5, or a conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 10-12, or a pharmaceutical composition according to claim 13 for use in the prevention and / or treatment and / or adjuvant treatment and / or neoadjuvant treatment of a disease associated with CDCP1; preferably the CDCP1-associated disease is a tumor, more preferably the tumor is selected from a solid tumor or a hematological tumor; Even more preferably, the solid tumor is selected from esophageal cancer, gastrointestinal cancer, pancreatic cancer, thyroid cancer, colorectal cancer, kidney cancer, lung cancer (e.g., lung adenocarcinoma, squamous cell lung cancer or small cell lung cancer), liver cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, head and neck cancer, bladder cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, germ cell cancer, bone cancer, skin cancer, thymus cancer, cholangiocarcinoma, gallbladder cancer, melanoma, mesothelioma, sarcoma and glioblastoma; wherein the hematological tumor is selected from lymphoma, myeloma (e.g., multiple myeloma) and leukemia.

17. An antibody or antigen-binding fragment thereof according to any one of claims 1-4, or a multispecific antibody according to claim 5, or a conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 10-12, or a pharmaceutical composition according to claim 13 for use in the diagnosis or differential diagnosis of a disease associated with CDCP1; preferably, the CDCP1-associated disease is a tumor; more preferably, the tumor is selected from a solid tumor or a hematological tumor; even more preferably, the solid tumor is selected from esophageal cancer, gastrointestinal cancer, pancreatic cancer, thyroid cancer, colorectal cancer, kidney cancer, lung cancer (e.g., lung adenocarcinoma, squamous cell lung cancer or small cell lung cancer), liver cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, head and neck cancer, bladder cancer, breast cancer, uterine cancer, cervical cancer, ovarian cancer, prostate cancer, testicular cancer, germ cell cancer, bone cancer, skin cancer, thymus cancer, cholangiocarcinoma, gallbladder cancer, melanoma, mesothelioma, sarcoma and glioblastoma; in this case, the hematological tumor is selected from lymphoma, myeloma (eg, multiple myeloma), and leukemia.